Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Equity Average (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Equity Average for 16 consecutive years, with $36.7 million as the latest value for Q1 2026.

  • Quarterly Equity Average fell 12.37% to $36.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Jan 2026, down 12.37% year-over-year, with the annual reading at $39.8 million for FY2025, 20.73% down from the prior year.
  • Equity Average for Q1 2026 was $36.7 million at PharmaCyte Biotech, down from $39.4 million in the prior quarter.
  • The five-year high for Equity Average was $91.7 million in Q1 2022, with the low at $29.5 million in Q2 2024.
  • Average Equity Average over 5 years is $56.5 million, with a median of $46.1 million recorded in 2025.
  • The sharpest move saw Equity Average soared 1322.03% in 2022, then plummeted 60.6% in 2024.
  • Over 5 years, Equity Average stood at $83.7 million in 2022, then tumbled by 54.6% to $38.0 million in 2023, then increased by 20.01% to $45.6 million in 2024, then decreased by 13.53% to $39.4 million in 2025, then fell by 6.95% to $36.7 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $36.7 million, $39.4 million, and $47.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.